ERBB2 and breast carcinoma: Among women with HER2+ breast cancer, trastuzumab was used in 57.8% of women with any prior CVD, in 25.9% of women with heart failure, 37.0% of those with CAD, 48.1% with hypertension, 35.2% with stroke, and 53.2% with history of VTE (Fig. 1).